Dr. Rugo Discusses the Future of Angiogenesis in Breast Cancer

Dr. Rugo on the Efficacy of Bevacizumab in Breast CancerПодробнее

Dr. Hope Rugo Examines Angiogenesis Inhibition for Advanced Breast CancerПодробнее

Dr. Rugo on the Future of Extended Adjuvant Hormone Therapy for Breast CancerПодробнее

Dr. Rugo on Anti-Angiogenesis Therapy Response PredictorsПодробнее

Dr. Rugo on Guidelines for the Treatment of Metastatic Breast CancerПодробнее

Dr. Rugo Discusses Guidelines for Metastatic Breast Cancer ManagementПодробнее

Dr. Rugo on Hormone Therapy for Patients With Breast CancerПодробнее

Dr. Rugo on VEGF-A as an Avastin Response PredictorПодробнее

Dr. Rugo on Proliferation as an Anti-Angiogenesis MarkerПодробнее

Dr. Rugo on 20-Year Span of Breast Cancer AdvancementsПодробнее

Dr. Rugo on Chemotherapy for Metastatic Breast CancerПодробнее

Dr. Rugo on Pathway Blockade in Breast CancerПодробнее

Dr. Rugo on Pathway Changes in Breast CancerПодробнее

Dr. Rugo on Ongoing Trials in HER2+ Breast CancerПодробнее

Dr. Rugo on SWISH Trial for HR-Positive Breast CancerПодробнее

Dr. Rugo on Rationale for the ELAINE Study in ESR1-Mutated ER+/HER2- Breast CancerПодробнее

Dr. Rugo on the Significance of the MONARCH I Trial for Breast CancerПодробнее

The Evolution of Endrocrine Therapy in Breast CancerПодробнее

Dr. Rugo on Extended Adjuvant Hormone Therapy for Breast CancerПодробнее